ENANTA PHARMACEUTICALS, INC Assets, Fair Value Disclosure
ENANTA PHARMACEUTICALS, INC (ENTA) had Assets, Fair Value Disclosure of $203.61 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes › Fair Value, Net Asset (Liability)
us-gaap:AssetsFairValueDisclosure · last filed 2026-08-12
- 2026-06-30: Assets, Fair Value Disclosure $203.61M.
- 2026-03-31: Assets, Fair Value Disclosure $226.62M.
- 2025-12-31: Assets, Fair Value Disclosure $240.37M.
- 2025-09-30: Assets, Fair Value Disclosure $168.15M.
| Period end | Assets, Fair Value Disclosure |
|---|---|
| 2026-06-30 | $203.61M 10-Q · filed 2026-08-12 |
| 2026-03-31 | $226.62M 10-Q · filed 2026-05-13 |
| 2025-12-31 | $240.37M 10-Q · filed 2026-02-11 |
| 2025-09-30 | $168.15M 10-Q · filed 2026-08-12 |
| 2025-06-30 | $187.42M 10-Q · filed 2025-08-13 |
| 2025-03-31 | $191.16M 10-Q · filed 2025-05-14 |
| 2024-12-31 | $214.12M 10-Q · filed 2025-02-12 |
| 2024-09-30 | $244.40M 10-K · filed 2025-11-19 |
| 2024-06-30 | $272.34M 10-Q · filed 2024-08-07 |
| 2024-03-31 | $300.04M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $336.12M 10-Q · filed 2024-02-08 |
| 2023-09-30 | $369.63M 10-K · filed 2024-11-27 |
| 2023-06-30 | $387.30M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $222.51M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $220.48M 10-Q · filed 2023-02-08 |
| 2022-09-30 | $248.43M 10-K · filed 2023-11-22 |
| 2022-06-30 | $277.90M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $317.91M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $334.84M 10-Q · filed 2022-02-10 |
| 2021-09-30 | $350.03M 10-K · filed 2022-11-23 |
| 2021-06-30 | $369.62M 10-Q · filed 2021-08-09 |
| 2021-03-31 | $399.45M 10-Q · filed 2021-05-10 |
| 2020-12-31 | $394.38M 10-Q · filed 2021-02-09 |
| 2020-09-30 | $413.65M 10-K · filed 2021-11-24 |
| 2020-06-30 | $423.16M 10-Q · filed 2020-08-10 |
| 2020-03-31 | $430.32M 10-Q · filed 2020-05-11 |
| 2019-12-31 | $410.66M 10-Q · filed 2020-02-10 |
| 2019-09-30 | $393.59M 10-K · filed 2020-11-25 |
| 2019-06-30 | $383.12M 10-Q · filed 2019-08-09 |
| 2019-03-31 | $380.76M 10-Q · filed 2019-05-10 |
| 2018-12-31 | $355.19M 10-Q · filed 2019-02-08 |
| 2018-09-30 | $323.23M 10-K · filed 2019-11-27 |
| 2018-06-30 | $291.31M 10-Q · filed 2018-08-09 |
| 2018-03-31 | $273.51M 10-Q · filed 2018-05-10 |
| 2017-12-31 | $281.11M 10-Q · filed 2018-02-09 |
| 2017-09-30 | $280.65M 10-K · filed 2018-11-29 |
| 2017-06-30 | $220.18M 10-Q · filed 2017-08-09 |
| 2017-03-31 | $234.57M 10-Q · filed 2017-05-10 |
| 2016-12-31 | $241.04M 10-Q · filed 2017-02-09 |
| 2016-09-30 | $240.92M 10-K · filed 2017-12-11 |
| 2016-06-30 | $240.40M 10-Q · filed 2016-08-09 |
| 2016-03-31 | $242.01M 10-Q · filed 2016-05-10 |
| 2015-12-31 | $230.87M 10-Q · filed 2016-02-09 |
| 2015-09-30 | $209.04M 10-K · filed 2016-12-09 |
| 2015-06-30 | $208.57M 10-Q · filed 2015-08-10 |
| 2015-03-31 | $223.41M 10-Q · filed 2015-05-08 |
| 2014-12-31 | $125.51M 10-Q · filed 2015-02-06 |
| 2014-09-30 | $131.31M 10-K · filed 2015-12-11 |
| 2014-06-30 | $133.19M 10-Q · filed 2014-08-12 |
| 2014-03-31 | $99.14M 10-Q · filed 2014-05-12 |
| 2013-12-31 | $104.01M 10-Q · filed 2014-02-13 |
| 2013-09-30 | $110.84M 10-K · filed 2014-12-11 |
| 2013-06-30 | $112.86M 10-Q · filed 2013-08-12 |
| 2013-03-31 | $119.29M 10-Q · filed 2013-05-15 |
| 2012-09-30 | $41.38M 10-K · filed 2013-12-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |